Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What CAGR And Valuation Are Anticipated For The Next-Generation Antibody Therapeutics Market?

The market size of next-generation antibody therapeutics has been expanding at a swift pace in the past few years. It is projected to escalate from $6.82 billion in 2024 to $7.56 billion in 2025, with a compound annual growth rate (CAGR) of 10.8%. Factors such as success in monoclonal antibody, increased chronic disease prevalence, authorization of antibody-drug conjugates, and augmentation in immunotherapy, gene therapy and antibodies have been instrumental to this historical growth period.

In the forthcoming years, the market size of next-generation antibody therapeutics is projected to experience a swift expansion. The market is anticipated to escalate to $11.34 billion in 2029 with a compound annual growth rate (CAGR) of 10.7%. The escalation during the prediction period can be connected to the development of biosimilar, bispecific antibodies, and nanobody, patient-centered strategies, immunomodulatory antibodies, and broadened applications in autoimmune diseases, including continuous manufacturing. The forecast period will also witness significant trends such as progress in antibody engineering, the advent of digital technologies in antibody design, industry collaborations, advancements in drug delivery systems, and the utilization of real-world evidence in antibody development.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12678&type=smp

What Market Forces Are Contributing To The Growth Of The Next-Generation Antibody Therapeutics Market?

The escalating recurrence of long-term ailment is anticipated to impel the expansion of the next-generation antibody therapeutics market in the future. Such illnesses are issues persisting over a year, requiring constant medical attention, limiting daily activities, or both. Next-generation antibody therapeutics offer a medicinal advantage to individuals affected by chronic conditions by providing more targeted care, thus potentially improving patient outcomes. For example, data from the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, projected in January 2023 that by 2050, the number of people aged 50 and above with at least one persistent affliction will skyrocket by 99.5% to 142.66 million. Consequently, the rising prevalence of chronic diseases is steering the advancement of the next-generation antibody therapeutics market.

Which Segmentation Factors Are Critical In The Next-Generation Antibody Therapeutics Market Analysis?

The next-generation antibody therapeuticsmarket covered in this report is segmented –

1) By Types Of Antibodies: Monoclonal Antibodies; Polyclonal Antibodies; Biospecific Antibodies; Antibody-Drug Conjugates; Other Types

2) By Therapeutic Area: Oncology; Autoimmune Diseases; Infectious Diseases; Neurodegenerative Disorders; Other Therapeutic Areas

3) By End-User: Hospitals And Clinics; Research Institutes; Pharmaceutical And Biotechnology Companies; Other End-Users

Subsegments:

1) By Monoclonal Antibodies: IgG Monoclonal Antibodies; IgM Monoclonal Antibodies

2) By Polyclonal Antibodies: Serum-Derived Polyclonal Antibodies; Hybridoma-Derived Polyclonal Antibodies

3) By Bispecific Antibodies: Dual-Targeting Antibodies; Single-Chain Variable Fragment (scFv) Antibodies

4) By Antibody-Drug Conjugates (ADCs): Targeted ADCs; Payload Types

5) By Other Types: Nanobodies; Engineered Antibodies

What New Opportunities Are Emerging From Trends In The Next-Generation Antibody Therapeutics Market?

The rise in technological advancements presents a notable tendency in the next-generation antibody therapeutics market. Top-tier companies in this market are determined to make technological progress like Molecular Indexing of Proteins by Self-Assembly (MIPSA), a proprietary technology to amplify protein identification and characterization. This leads to precise and potent treatments. Such advancements have an aim to refine therapeutic profiles, lessen expenses, and tackle intricate diseases with exceedingly precise measures. Molecular Indexing of Proteins by Self-Assembly (MIPSA) is a technology that systematically organizes protein molecules into structured frameworks for boosting analysis and quantification, which escalates sensitivity and correctness in protein discovery, beneficial in research and diagnostic processes. For example, Infinity Bio, Inc., an American biotechnology firm, in January 2024, introduced a next-generation antibody profiling platform that employs MIPSA technology for efficient, cost-saving analysis of immune responses, with an endeavor to augment disease comprehension and individualize treatment strategies.

Which Organizations Are At The Forefront Of The Next-Generation Antibody Therapeutics Market?

Major companies operating in the next-generation antibody therapeutics market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Moderna Inc., BioNTech SE, Regeneron Pharmaceuticals Inc., Biogen Inc., Celgene Corporation, Lonza Group AG, Catalent Inc., Genentech Inc., Kyowa Hakko Kirin Co. Ltd., Samsung Biologics, WuXi Biologics, Seagen Inc., Seattle Genetics Inc., Xencor Inc., ImmunoGen Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report

Which Region Is Leading Innovation In The Next-Generation Antibody Therapeutics Market?

North America was the largest region in the next-generation antibody therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation antibody therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=12678&type=smp

Browse Through More Reports Similar to the Global Next-Generation Antibody Therapeutics Market 2025, By The Business Research Company

Antibody Drug Conjugates Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report

Next Generation Sequencing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/next-generation-sequencing-global-market-report

Next Generation Data Storage Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/next-generation-data-storage-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model